A detailed history of Bessemer Group Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 72 shares of KRYS stock, worth $13,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares
72
Previous 40 80.0%
Holding current value
$13,708
Previous $7,000 85.71%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$174.7 - $213.66 $5,590 - $6,837
32 Added 80.0%
72 $13,000
Q2 2024

Aug 13, 2024

BUY
$153.12 - $183.64 $6,124 - $7,345
40 New
40 $7,000
Q3 2020

Nov 12, 2020

SELL
$37.76 - $48.49 $1.11 Million - $1.43 Million
-29,500 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$37.03 - $60.0 $648,025 - $1.05 Million
17,500 Added 145.83%
29,500 $1.22 Million
Q1 2020

Apr 30, 2020

BUY
$35.02 - $65.64 $420,240 - $787,680
12,000 New
12,000 $519,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.